SCHEMBL30766019

SCHEMBL30766019

CCCCOC(=O)Cn1c(N2CCOCC2)ncc(Br)c1=O

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.54
TSHR P16473 2/20 0.46
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
GAA P10253 2/20 0.41
POLB P06746 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ADORA1 P30542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765514 0.89 ALDH1A1 (0.48) LMNATSHRSMN1; SMN2NPC1MAPT
SCHEMBL30765839 0.78 MEN1 (0.49) LMNATSHRSMN1; SMN2MAPTKMT2A
SCHEMBL30765661 0.77 MEN1 (0.48) LMNATSHRSMN1; SMN2MAPTKMT2A
SCHEMBL30766142 0.76 HDAC6 (0.40) LMNATSHRSMN1; SMN2KMT2AMEN1
SCHEMBL30765999 0.75 PDE4B (0.44) LMNATSHRMAPTKMT2AMEN1
SCHEMBL30766020 0.75 MEN1 (0.46) LMNATSHRSMN1; SMN2MAPTKMT2A
SCHEMBL30765740 0.74 MEN1 (0.45) LMNATSHRSMN1; SMN2MAPTKMT2A
SCHEMBL30765447 0.73 L3MBTL1 (0.65) LMNATSHRSMN1; SMN2MAPTKMT2A
SCHEMBL30765592 0.70 L3MBTL1 (0.50) LMNATSHRSMN1; SMN2MAPTKMT2A
SCHEMBL12120129 0.69 LMNA (0.59) LMNATSHRSMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed